Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.30
    OpenPayerBilling CodesGenomic Sequencing Procedures and Other Molecular Multianalyte AssaysCPT cpt-81414-cardiac-ion-channelopathy-cnv-panel
    Ask Trek AI about this page

    CPT 81414: Cardiac Ion Channelopathy Copy Number Variant Panel

    Commercial payers pay $592 on average nationally for this procedure.

    CPT code 81414 describes a laboratory panel that detects genetic duplications and deletions (copy number variants) involving at least two genes associated with cardiac ion channelopathies, performed by a clinical laboratory or pathology service; this is a molecular diagnostic genetic test typically provided as a send-out or reference laboratory service with specimen collection and testing performed in an outpatient laboratory or specialized molecular diagnostic facility.

    For related coverage guidance, see recent payer policy updates: Oral Cancer Screening and Testing, RTM Testing for Alpha-1 Antitrypsin Deficiency, Cytochrome P450 Genotype-Guided Treatment Strategy Corporate Medical Policy.

    Customize your policy alerts

    Sign up for cpt 81414 policy alerts

    Get alerted when payer policies referencing 81414 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    National Reimbursement Benchmarks

    National commercial reimbursement for CPT 81414 centers on a BUCA (average commercial) rate of $592.30, with payer-specific means clustering above and below that mark. Blue Cross Blue Shield’s mean of $676 and Cigna’s mean of $605.20 sit near BUCA, while Aetna’s mean of $417.50 and UnitedHealth Group’s mean of $503 are lower. Blue Cross Blue Shield and Cigna display high upper tails, with maximums of $2345.50 and $1901.60 respectively, whereas Aetna’s maximum is comparatively modest at $758.

    Dispersion measured by the interquartile range (P75–P25) highlights variability: Blue Cross Blue Shield’s IQR is $260.00 (from $472.70 to $756.70), Cigna’s IQR is $447.70 (from $343.90 to $786.60), UnitedHealth Group’s IQR is $321.60 (from $256.30 to $584.90), BUCA’s IQR is $287.00 (from $380.70 to $694.70), and Aetna’s IQR is $300.40 (from $266.00 to $526.40). Cigna shows the widest IQR at $447.70, indicating the greatest middle-50% spread, while Blue Cross Blue Shield’s narrower IQR at $284.00 indicates the tightest middle-range among the listed payers.

    Table of contents

    Progress1 / 9

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools
    National Payer Mean Reimbursement Rates

    State Reimbursement Rates

    State: Alaska1 / 51

    Rate by payer

    Clinical & Coding Specifications

    Clinical Context

    A 28-year-old patient with a family history of sudden cardiac death and episodes of palpitations is referred by a cardiologist for genetic testing to evaluate suspected cardiac ion channelopathy. The patient has an abnormal electrocardiogram showing prolonged QT interval and a prior Holter monitor demonstrating episodic ventricular ectopy. The clinician orders a targeted genomic deletion/duplication panel that includes at least two genes implicated in channelopathies to detect copy number variants (deletions or duplications) that sequencing alone may miss. A blood specimen is collected in an appropriate EDTA tube at an outpatient phlebotomy clinic or hospital laboratory (typical site of service: clinical laboratory/pathology). The specimen is accessioned by the laboratory, DNA is extracted, and a molecular cytogenetic or multiplex ligation-dependent probe amplification (MLPA) or comparable assay is performed to identify gene-level duplications and deletions. Results are reviewed by a board-certified molecular pathologist or laboratory director and a report is issued to the ordering cardiologist or referring family medicine physician, with variant interpretation referencing established guidelines for clinical significance and recommendations for familial cascade testing when appropriate.

    Related CPT Codes

    CPT CodeDescriptionRelationship to This Procedure
    81413Cardiac ion channelopathies; genomic sequence analysis panel, must include sequencing of at least 10 genesRelated genomic sequencing panel that may be ordered alongside or prior to deletion/duplication testing to identify single-nucleotide variants; complements by detecting copy number variants not found by sequencing.

    Related Modifiers

    5 rows

    ModifierDescriptionWhen to Use
    26Modifier 26 (Professional Component) identifies and bills only the professional portion of a split service — the physician’s interpretation, report, and medical judgment — when the technical…- Use CPT Modifier -26 when you are billing only the professional component (PC) of a split‑bill eligible service—i.e., you performed the physician interpretation, medical judgment and prepared a…
    59Modifier 59 indicates a distinct procedural service when two procedures that are not normally billed together are clinically and procedurally separate. The CPT definition (as reiterated by CMS)…- Use modifier -59 to report a distinct procedural service when documentation supports that the procedure reported is not normally billed together with another service on the same day because of a…
    62Modifier 62 indicates that two surgeons function as co‑surgeons, each performing distinct parts of the same primary surgical procedure. It is appended to the primary procedure code (and any…- Use modifier -62 when two surgeons act as co‑surgeons (both primary surgeons) on a single definitive primary procedure, each performing distinct parts of the same surgical procedure (append -62 to…
    90Modifier ‑90 (Reference/Outside Laboratory) indicates that a laboratory test was performed by an entity other than the treating or reporting provider. The American Medical Association defines…- Use CPT modifier -90 when a laboratory test is performed by an outside/reference laboratory (an entity other than the treating or reporting physician or qualified professional) and the claim needs…
    91Modifier 91 — “Repeat Clinical Diagnostic Laboratory Test” — is appended when the exact same CPT laboratory test is performed more than once for the same patient on the same day because serial,…- Use modifier 91 when the exact same CPT laboratory test is performed more than once on the same patient on the same date because serial or repeated testing is medically necessary to monitor…

    Related Provider Taxonomies

    8 rows

    Taxonomy Code
    207ZP0102X
    207L00000X
    207Q00000X
    163WN0800X
    363LS0200X
    363LP0200X
    2080P0216X
    246RP1900X

    Related ICD-10-CM Codes

    33 rows

    ICD-10-CM CodeDescription
    E75.21Fabry (-Anderson) disease
    E78.01
    F82Specific developmental disorder of motor function
    I20.0Unstable angina
    I20.9Angina pectoris, unspecified
    I21.9Acute myocardial infarction, unspecified
    I25.10Atherosclerotic heart disease of native coronary artery without angina pectoris
    I25.110Atherosclerotic heart disease of native coronary artery with unstable angina pectoris
    I34.0Nonrheumatic mitral (valve) insufficiency
    I34.1Nonrheumatic mitral (valve) prolapse

    Showing 1–10 of 33

    Related Payer Policy Updates

    Specialty: Genetic & Molecular Testing1 / 3

    10 rows

    PolicyPayerEffective Date
    Oral Cancer Screening and TestingOscar Health2027-01-01
    RTM Testing for Alpha-1 Antitrypsin DeficiencyOscar Health2027-01-01
    Cytochrome P450 Genotype-Guided Treatment Strategy Corporate Medical Policybcbsvermont2027-01-01
    Carrier Testing Panels for Genetic Diseases (for Kentucky Only)UnitedHealthcare2026-10-01
    Genetic Testing for Neurological Disorders (for Kansas Only)UnitedHealthcare2026-10-01
    Genetic and Molecular TestingProvidence Health Plan2026-10-01
    Cell-Free Fetal DNA Testing (for Idaho Only)UnitedHealthcare2026-10-01
    Next Generation Sequencing for Minimal Residual Disease DetectionProvidence Health Plan2026-10-01
    Pharmacogenetic Panel Testing (for Kansas Only)UnitedHealthcare2026-10-01
    Non-Covered Genetic Panel TestsProvidence Health Plan2026-10-01

    Related Codes

    CPT-81410-GENOMIC-PANEL-AORTIC-DISEASE

    CPT 81410: Heritable Thoracic Aortic Disease Targeted Gene Panel

    CPT-81411-GENETIC-DUPLICATION-DELETION-PANEL-AORTIC-DISEASE

    CPT 81411: Genetic Panel for Aortic Dysfunction Copy Number Analysis

    CPT-81412-ASHKENAZI-JEWISH-GENOMIC-SEQUENCE-PANEL

    CPT 81412: Ashkenazi Jewish–Associated Genetic Sequence Panel

    CPT-81413-GENOMIC-PANEL-CARDIAC-ION-CHANNELOPATHIES

    CPT 81413: Cardiac Ion Channelopathy Targeted Gene Panel

    CPT-81415-EXOME-SEQUENCE-ANALYSIS-UNEXPLAINED-DISORDER

    CPT 81415: Exome Sequence Analysis for Unexplained Disorder

    CPT-81416-FAMILIAL-EXOME-SEQUENCE-ANALYSIS

    CPT 81416: Relative Exome Sequence Analysis for Reference Exome

    CPT-81417-EXOME-SEQUENCE-REEVALUATION

    CPT 81417: Exome Reanalysis for New Clinical Information

    CPT-81418-PHARMACOGENOMIC-MULTIGENE-DRUG-METABOLISM-PANEL

    CPT 81418: Pharmacogenetic Multigene Panel Including CYP2C19 and CYP2D6

    CPT-81419-GENOMIC-SEQUENCE-PANEL-EPILEPSY

    CPT 81419: Genomic Sequence Analysis Panel for Epilepsy

    CPT-81420-NIPS-FETAL-ANEUPLOIDY-SEQUENCING-PANEL

    CPT 81420: Cell-Free Fetal DNA Panel for Chromosomes 13, 18, 21

    Showing 1–10 of 43

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

    81414
    81413